“Among eight expected key readouts, we anticipate one for SV, our novel potential first-in-class integrating beta-six targeting the DOT in ADC.”

In context

“d licensing agreement, and other Pfizer Inc. programs such as our oral GPR antagonist candidate. Since closing our Biohaven acquisition a few years ago, we have globally scaled a leading migraine portfolio. It strengthened our product mix to drive significant impact both for patients and our commercial performance. Nurtec has a strong market leadership position in the oral CGRP class in 2025. In Q4, we captured 83% of new CGRP writer volume and remain the leader in new patient starts. I expect 2026 to be also a very rich year for key catalysts and to intend to deliver on our critical R&D milestones. This year, we anticipate progress with approximately 20 recently initiated and planned key pivotal studies with 10 of them in the Metsera portfolio and four with our anti-PD-1 VEGF bispecific. Among eight expected key readouts, we anticipate one for SV, our novel potential first-in-class integrating beta-six targeting the DOT in ADC. The readout will be in second-line plus non-squamous metastatic non-small cell lung cancer, which affects about 50,000 patients in the US and more than 200,000 patients globally. We are also expecting key phase three readouts for elbrexvio in double-class exposed relapsed refractory multiple myeloma and for our Lyme disease vaccine candidate. The foundation of our strategy in obesity and adjacent conditions is targeting breakthrough medicines in what could be a $150 billion market. Earlier today, we announced encouraging results from our VSPERT three study, which previously was known as METERA 097I, the ultra-long-acting investigational next-generation injectable GLP-1 receptor agonist. In a few moments, Chris Boshoff, our Chief Scientific Officer, will walk through additional details and”